Finch Therapeutics Group, Inc. (FNCH)
FNCH Stock Price Chart
Explore Finch Therapeutics Group, Inc. interactive price chart. Choose custom timeframes to analyze FNCH price movements and trends.
FNCH Company Profile
Discover essential business fundamentals and corporate details for Finch Therapeutics Group, Inc. (FNCH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Mar 2021
Employees
1.00
CEO
Matthew P. Blischak
Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
FNCH Financial Timeline
Browse a chronological timeline of Finch Therapeutics Group, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 13 Aug 2024
EPS came in at -$3.01 .
Earnings released on 10 May 2024
EPS came in at -$2.41 .
Earnings released on 25 Mar 2024
EPS came in at -$1.89 , while revenue for the quarter reached $2.85M .
Earnings released on 8 Nov 2023
EPS came in at -$1.51 .
Earnings released on 10 Aug 2023
EPS came in at -$4.33 surpassing the estimated -$4.51 by +3.99%.
Stock split effective on 12 Jun 2023
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 May 2023
EPS came in at -$15.62 falling short of the estimated -$2.70 by -478.52%, while revenue for the quarter reached $107.00K .
Earnings released on 31 Dec 2022
EPS came in at -$16.48 , while revenue for the quarter reached $8.00K .
Earnings released on 10 Nov 2022
EPS came in at -$13.51 falling short of the estimated -$12.01 by -12.49%, while revenue for the quarter reached $138.00K .
Earnings released on 11 Aug 2022
EPS came in at -$14.41 falling short of the estimated -$13.81 by -4.34%, while revenue for the quarter reached $361.00K .
Earnings released on 16 May 2022
EPS came in at -$15.62 falling short of the estimated -$0.32 by -4.78K%, while revenue for the quarter reached $354.00K , missing expectations by -92.92%.
Earnings released on 31 Dec 2021
EPS came in at -$12.04 , while revenue for the quarter reached $806.00K .
Earnings released on 10 Nov 2021
EPS came in at -$6.31 surpassing the estimated -$12.61 by +49.96%, while revenue for the quarter reached $11.34M , missing expectations by -25.93%.
Earnings released on 10 Aug 2021
EPS came in at -$9.61 falling short of the estimated -$8.41 by -14.27%, while revenue for the quarter reached $2.83M , meeting expectations.
Earnings released on 13 May 2021
EPS came in at -$1.00 falling short of the estimated -$0.24 by -316.67%, while revenue for the quarter reached $3.55M , missing expectations by -48.72%.
Earnings released on 9 Jan 2021
EPS came in at -$46.85 , while revenue for the quarter reached $1.81M .
Earnings released on 30 Sept 2020
EPS came in at -$36.65 , while revenue for the quarter reached $1.77M .
FNCH Stock Performance
Access detailed FNCH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.